MiR-125/HER2 pathway as a target in small-cell lung cancer.
Abstract:
Small-cell lung cancer (SCLC) accounts for 15% of all lung cancer cases and is a highly lethal disease. For the last several decades, the standard treatment for SCLC has been deadlocked, and new therapeutic strategies are urgently needed. Human epidermal growth factor receptor 2 (HER2) is a member of the HER family and has been reported to be overexpressed in 30% of SCLC cases with poor prognosis. However, the clinical relevance of HER2-targeted therapy for SCLC remains unclear. Here, we firstly identify that cytotoxic drugs induce significant HER2 overexpression through microRNA-125a (miR-125a) and miR-125b downregulation, which in turn act as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in SCLC. In this study, we showed that treatment of the HER2-positive SCLC cells, SBC-3 and SBC-5, with cytotoxic drugs induced a significant upregulation of HER2. Cisplatin (CDDP) treatment of SCLC cells resulted in a significant downregulation of miR-125a and miR-125b. We confirmed that miR-125a and miR-125b bound to the 3'-untranslated regions of HER2 mRNA, and that downregulation of miR-125a and miR-125b resulted in upregulation of HER2 in SCLC cells, suggesting a relationship between cytotoxic drug exposure and miR-125/HER2 dysregulation.
Furthermore, using a calcein assay we demonstrated a significantly enhanced cytotoxic effect of CDDP and trastuzumab that was mediated via antibody-dependent cellular cytotoxicity. Finally, we clearly demonstrated the enhanced anti-tumor effect of these agents in an orthotopic lung cancer model in vivo. Our result offer a novel therapeutic strategy for HER2-positive SCLC by using trastuzumab combined with cytotoxic drugs.
Introduction
Lung cancer is the leading cause of cancer related deaths all over the world.
Small-cell lung cancer (SCLC) accounts for 15% of all lung cancer cases (1). Approximately 70% of all newly diagnosed SCLC patients present with advanced disease and require systemic chemotherapy. Despite a dramatic response to front-line chemotherapy, drug-resistance is the fundamental issues that cannot be avoided, and SCLC is still an inevitably fatal disease. The recent development of molecular targeted agents for epidermal growth factor receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK)
translocation have greatly changed the therapeutic strategy for, and have prolonged survival time in non-small cell lung cancer (NSCLC) (2, 3) . In the meantime, the therapeutic strategy for SCLC has remained as platinum-based combination chemotherapy for the last several decades (4) . Although a few recent SCLC sequencing studies have reported novel putative driver gene alterations, specific molecular targeting therapy against such alteration is not yet available (5-7) .
Human epidermal growth factor receptor 2, also known as HER2 or erbB2/neu, is a member of the erbB receptor tyrosine kinase family. HER2, which is encoded by the ERBB2 gene, activates cellular proliferation and survival signals mainly as a heterodimer with other HER family members (8) (9) (10) . HER2 has been reported to be overexpressed in 30% of breast cancers and in 20-30% of gastric cancers, correlating with their poor prognosis (11, 12) .
Similarly, HER2 is reported to be overexpressed in approximately 30% of SCLCs and is known to be a negative prognostic factor for SCLC (13) (14) (15) . Trastuzumab, a monoclonal anti-HER2 antibody, has been approved for the treatment of HER2-positive breast and gastric cancers and is a widely used indispensable drug. Despite the importance of trastuzumab combined with standard chemotherapy for the treatment of HER2-positive breast and gastric cancers, the precise mechanisms of their enhanced effect remain unknown. Moreover, the efficacy of trastuzumab alone or in combination with standard chemotherapy for SCLC has yet to be clarified.
MicroRNAs (miRNAs), a family of short endogenous noncoding RNAs, act as posttranscriptional gene regulators through binding their target messenger RNAs (mRNA) (16) . It was recently shown that miRNA-125a-5p (miR-125a) and its homolog miRNA-125b
(miR-125b) directly regulate HER2 in human breast cancer cells (17) . Likewise, miR-125a expression has been shown to have prognostic significance for gastric cancer (18) . The impact of miR-125a or miR-125b on HER2 expression in SCLC remains unknown.
Based on the above data, we hypothesized that cytotoxic drugs might boost HER2 expression via changes in miR-125a or miR-125b expression, and that this upregulated HER2 expression could be targeted by trastuzumab for SCLC treatment. In this study, we demonstrated that exposure of HER2-positive SCLC cells to cytotoxic drugs resulted in
downregulation of miR-125a and miR-125b, and accordingly HER2 overexpression. Notably, the combination therapy of trastuzumab and CDDP showed an enhanced anti-tumor effect in vitro that was mediated via antibody-dependent cellular cytotoxicity (ADCC). This enhanced effect was confirmed using an orthotopic lung cancer model in vivo. These data suggest the importance of ADCC in trastuzumab-mediated antitumor activity. They further suggest that cytotoxic drug-induced regulation of the miR-125/HER2 pathway is one of the hidden mechanisms behind the enhanced anti-tumor effect of trastuzumab and cytotoxic drugs and that this mode of cytotoxicity involves ADCC. Our study offers a novel therapeutic strategy for HER2-positive SCLC by combination therapy with trastuzumab and cytotoxic drugs.
Materials and Methods
Cell culture. Figure 2D ). The levels of both miR-125a and miR-125b were significantly downregulated 24 hr and 48 hr after CDDP treatment compared to those of control cells.
HER2 is directly regulated by microRNA-125a and microRNA-125b in SCLC.
To confirm the binding of miR-125a-5p and miR-125b to the 3'-UTR of the mRNA encoding HER2 in SCLC, a luciferase reporter assay was carried out using a vector that included the 3'-UTR sequence of HER2 downstream from the luciferase reporter gene (ERBB2-Luc w/t) ( Figure   3A ). Transient co-transfection of the reporter plasmid and pre-miR-125a or pre-miR-125b
into SBC-5 cells significantly reduced luciferase activity compared with the negative control ( Figure 3B ). In contrast, the luciferase activity of the reporter construct with a mutated 3'-UTR sequence (ERBB2-Luc mut) was unchanged by co-transfection with either pre-miR-125a or pre-miR-125b ( Figure 3B ). These data suggest that HER2 mRNA is a direct functional target of miR-125a and miR-125b in SCLC cells.
Downregulation of microRNA-125a or microRNA-125b promotes HER2
overexpression. To investigate the relationship between dysregulation of miR-125a or miR-125b and HER2 expression, we compared the effects of transient transfection of SBC-3
and SBC-5 cells with pre-miR-125a, pre-miR-125b, anti-miR-125a, or anti-miR-125b on HER2 mRNA and protein expression. As shown in Figure 3C , the expression of HER2 mRNA in SBC-5 cells did not change after transient transfection of anti-miR-125a and anti-miR-125b, whereas significant HER2 mRNA downregulation was observed after transfection of pre-miR-125a and pre-miR-125b. WB analysis indicated that HER2 protein expression was upregulated in anti-miR-125a and anti-miR-125b treated cells whereas it was downregulated in pre-miR-125a and pre-miR-125b treated cells ( Figure 3D ). These data suggest that downregulation of both miR-125a and miR-125b could directly induce HER2 upregulation. Moreover, these results may indicate that CDDP-induced miR-125 downregulation could be a novel mechanism of HER2 overexpression after cytotoxic chemotherapy. In order to understand the mechanism of HER2 upregulation that we observed after drug exposure, our study focused on miR-125a and miR-125b. We clearly demonstrated the downregulation of miR-125a and miR-125b at 24 hr after exposure of SCLC to CDDP, and demonstrated that this downregulation was accompanied by HER2 upregulation. Moreover, we confirmed that HER2 is a direct target of both miR-125a and miR-125b in SCLC cells.
Growth inhibitory effect of
These results suggest that cytotoxic drug-induced miR-125a and miR-125b downregulation might be a novel mechanism of HER2 upregulation after drug exposure.
In this study, we investigated the function of miR-125a and miR-125b for the regulation of HER2 in SCLC. In breast cancer cells, miR-125b has been reported to suppress the oncoproteins MUC1, HER2 and HER3, inhibiting the growth of breast cancer cells and promoting their sensitivity to chemotherapy (17, 26) . Considering that miR-125/HER2 pathway may have a crucial role in chemoresistant SCLC, our results can also offer a possibility of miR-125 replacement therapy for preventing drug-resistance in HER2-positive SCLC.
We could not demonstrate the mechanism of miR-125a and miR-125b dysregulation after cytotoxic drug exposure. MiR-125, especially miR-125b, has been reported to be regulated by nuclear factor kappa beta (NF-κβ) depend on the cellular context (27, 28) .
Meanwhile, cytotoxic chemotherapies such as CDDP, ETP, and CPT-11 are well known for activating NF-κβ (29) (30) (31) . In this context, although we could not demonstrate the significant could be also applied to understanding the enhanced effect of trastuzumab and cytotoxic drugs against breast or gastric cancer. Moreover, we confirmed the enhanced effect of a combination of trastuzumab and CDDP using an orthotopic lung cancer model that was monitored bioluminescence imaging. Using this model, we were able to reproduce tumor growth similar to that observed in the living human body.
In conclusion, we firstly identified a cytotoxic drug-induced miR-125/HER2 pathway as a novel mechanism underlying the enhanced effect of trastuzumab and cytotoxic drugs.
Secondly, combination therapy of trastuzumab and a cytotoxic drug exerted an enhanced anti-tumor effect via ADCC in vitro and in vivo. Our result offer a novel therapeutic strategy for HER2-positive SCLC by using trastuzumab combined with cytotoxic drugs. 
